RU99112123A - JEWELRY HAVING A NUCLEUS COATED WITH ANTI-FUN FUNCTION AND POLYMER - Google Patents

JEWELRY HAVING A NUCLEUS COATED WITH ANTI-FUN FUNCTION AND POLYMER

Info

Publication number
RU99112123A
RU99112123A RU99112123/14A RU99112123A RU99112123A RU 99112123 A RU99112123 A RU 99112123A RU 99112123/14 A RU99112123/14 A RU 99112123/14A RU 99112123 A RU99112123 A RU 99112123A RU 99112123 A RU99112123 A RU 99112123A
Authority
RU
Russia
Prior art keywords
dragee
polymer
antifungal agent
water
protective coating
Prior art date
Application number
RU99112123/14A
Other languages
Russian (ru)
Other versions
RU2218153C2 (en
Inventor
Роже Петрус Гереберн ВАНДЕКРУЙС
КОНДЕ Валентэн Флоран Виктор ДЕ
Поль Мари Виктор Жили
Йозеф Петерс
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Publication of RU99112123A publication Critical patent/RU99112123A/en
Application granted granted Critical
Publication of RU2218153C2 publication Critical patent/RU2218153C2/en

Links

Claims (9)

1. Драже, включающее а) центральное, округлой формы или сферическое ядро; б) пленку покрытия из водорастворимого полимера и противогрибкового средства, и в) слой полимера защитного покрытия, отличающееся тем, что ядро имеет диаметр от около 250 до около 600 мкм (30-60 меш).1. Dragee, including a) a central, rounded shape or spherical core; b) a coating film of a water-soluble polymer and an antifungal agent, and c) a polymer layer of a protective coating, characterized in that the core has a diameter of from about 250 to about 600 microns (30-60 mesh). 2. Драже по п. 1, включающее, по массе, в расчете на общую массу драже: а) 10 - 25% вещества ядра; b) 39 - 60% водорастворимого полимера; с) 26 - 40% противогрибкового средства; и d) 4 - 7% полимера защитного покрытия. 2. Dragee according to claim 1, including, by weight, based on the total weight of the dragee: a) 10 - 25% of the core substance; b) 39-60% water soluble polymer; c) 26 to 40% of an antifungal agent; and d) 4 to 7% of a protective coating polymer. 3. Драже по п. 2, где вещество ядра представляет собой сахарную сферу с размером 250-350 мкм (45-60 меш), водорастворимый полимер представляет собой гидроксипропилметилцеллюлозу и противогрибковое средство является итраконазолом. 3. Dragee according to claim 2, where the core substance is a sugar sphere with a size of 250-350 μm (45-60 mesh), the water-soluble polymer is hydroxypropyl methylcellulose and the antifungal agent is itraconazole. 4. Драже по п. 3, где масса/масса отношение противогрибковое средство: водорастворимый полимер составляет от около 1:1 до около 1:2. 4. Dragee according to claim 3, where the mass / mass ratio of the antifungal agent: water-soluble polymer is from about 1: 1 to about 1: 2. 5. Драже по п. 2, где полимер защитного покрытия представляет собой полиэтиленгликоль. 5. Dragee according to claim 2, wherein the protective coating polymer is polyethylene glycol. 6. Драже по п. 3, включающее приблизительно, a) 16,5 - 19% сахарных ядер; b) 43 - 48% гидроксипропилметилцеллюлозы 2910 5 мПаoс; c) 29 - 33% интраконазола или саперконазола; и d) 5 - 6% полиэтиленгликоля 20000.6. Dragee according to claim 3, comprising approximately, a) 16.5 - 19% of sugar cores; b) 43 to 48% hydroxypropyl methylcellulose 2910 5 MPa o s; c) 29 to 33% of intraconazole or saperconazole; and d) 5-6% polyethylene glycol 20,000. 7. Фармацевтическая лекарственная форма, включающая эффективное количество противогрибкового средства в виде драже по любому из пп. 1 - 6. 7. A pharmaceutical dosage form comprising an effective amount of an antifungal agent in the form of a dragee according to any one of claims. 16. 8. Лекарственная форма по п. 7, где лекарственная форма представляет собой твердую желатиновую капсулу. 8. The dosage form according to claim 7, where the dosage form is a hard gelatin capsule. 9. Способ получения драже по любому из пп. 1 - 6, включающий следующие стадии: a) нанесение покрытия на сахарные сферы размером 250 - 355 мкм (45-60 меш) посредством распыления на них раствора противогрибкового средства и водорастворимого полимера в органическом растворителе, состоящем из метиленхлорида и этанола, в грануляторе с псевдоожиженным слоем, снабженном Wurster (донным распылителем) вставкой; b) высушивание полученных покрытых ядер; и c) нанесение защитного покрытия на высушенные ядра распылением на них раствора полимера защитного покрытия в органическом растворителе, состоящем из метиленхлорида и этанола, в грануляторе с псевдоожиженным слоем, снабженном Wurster (донным распылителем) вставкой. 9. The method of producing dragees according to any one of paragraphs. 1 to 6, comprising the following steps: a) coating sugar spheres with a size of 250 - 355 μm (45-60 mesh) by spraying a solution of an antifungal agent and a water-soluble polymer in an organic solvent consisting of methylene chloride and ethanol in a fluidized granulator a layer provided with a Wurster (bottom sprayer) insert; b) drying the resulting coated cores; and c) applying a protective coating to the dried cores by spraying on them a solution of the polymer of the protective coating in an organic solvent consisting of methylene chloride and ethanol in a fluidized bed granulator equipped with a Wurster (bottom sprayer) insert.
RU99112123/15A 1997-03-26 1998-03-18 Nucleus-bearing drops coated with antifungal agent and polymer RU2218153C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200914 1997-03-26
EP97200914.6 1997-03-26

Publications (2)

Publication Number Publication Date
RU99112123A true RU99112123A (en) 2001-04-20
RU2218153C2 RU2218153C2 (en) 2003-12-10

Family

ID=8228147

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99112123/15A RU2218153C2 (en) 1997-03-26 1998-03-18 Nucleus-bearing drops coated with antifungal agent and polymer

Country Status (31)

Country Link
EP (1) EP0969821B1 (en)
JP (1) JP3608800B2 (en)
KR (1) KR100520936B1 (en)
CN (1) CN1206984C (en)
AP (1) AP1227A (en)
AT (1) ATE241969T1 (en)
AU (1) AU734248B2 (en)
BG (1) BG64434B1 (en)
BR (1) BR9806174A (en)
CA (1) CA2269501C (en)
CY (1) CY2384B1 (en)
CZ (1) CZ295502B6 (en)
DE (1) DE69815316T2 (en)
DK (1) DK0969821T3 (en)
EE (1) EE03904B1 (en)
ES (1) ES2201485T3 (en)
HK (1) HK1022840A1 (en)
HU (1) HU224217B1 (en)
ID (1) ID21477A (en)
IL (1) IL129575A (en)
NO (1) NO325102B1 (en)
NZ (1) NZ335364A (en)
OA (1) OA11162A (en)
PL (1) PL190566B1 (en)
PT (1) PT969821E (en)
RU (1) RU2218153C2 (en)
SI (1) SI0969821T1 (en)
SK (1) SK284813B6 (en)
TR (1) TR199900990T2 (en)
UA (1) UA60318C2 (en)
WO (1) WO1998042318A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100549095B1 (en) * 1998-07-17 2006-02-06 얀센 파마슈티카 엔.브이. Pellets having a core coated with an antifungal and a polymer
ES2157731B1 (en) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada ORAL PHARMACEUTICAL PREPARATION OF AN ANTIFUNGIC ACTIVITY COMPOUND AND PROCEDURE FOR PREPARATION.
CN1156461C (en) 1999-03-24 2004-07-07 R·P·希拉技术股份有限公司 Improved aqueous solubility pharmaceutical formulations
KR100432949B1 (en) * 2000-06-13 2004-05-31 코오롱제약주식회사 Itraconazole composition of the powders and granules type, its pharmaceutical preparation and method
US6663897B2 (en) * 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
IL157171A0 (en) 2001-02-14 2004-02-08 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino) -benzothiazole sulfonamide hiv protease inhibitors
JP4417010B2 (en) 2001-04-09 2010-02-17 テイボテク・フアーマシユーチカルズ・リミテツド Wide range 2- (substituted-amino) -benzoxazolesulfonamide HIV protease inhibitors
CA2444895C (en) 2001-05-11 2011-02-15 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
US8071133B2 (en) 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
PL216539B1 (en) 2001-12-21 2014-04-30 Tibotec Pharm Ltd Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
NZ536496A (en) 2002-05-17 2006-06-30 Tibotec Pharm Ltd Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors
KR100994759B1 (en) 2002-08-14 2010-11-16 티보텍 파마슈티컬즈 Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
KR100557680B1 (en) * 2002-11-23 2006-03-07 한국유나이티드제약 주식회사 Pellet preparations and methods for improved solubility of itraconazole
EP1438960B2 (en) * 2003-01-14 2012-12-19 Acino Pharma AG Compostion of itraconazole dispersed in a hydrophilic polymer having enhanced bioavailability
EP1438961B2 (en) * 2003-01-14 2014-08-20 Acino Pharma AG Bioequivalent composition of itraconazole dispersed in a hydrophilic polymer
JP2007501256A (en) 2003-08-06 2007-01-25 ムルイェ、ニルマル Pharmaceutical composition containing water-soluble drug
SG145742A1 (en) 2003-09-11 2008-09-29 Tibotec Pharm Ltd Entry inhibitors of the hiv virus
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
AR048650A1 (en) 2004-05-04 2006-05-10 Tibotec Pharm Ltd DERIVATIVES OF (1,10B-DIHIDRO-2- (AMINOCARBONIL-PHENYL) -5H-PIRAZOLO [1,5 C] [1,3] BENZOXAZIN-5-IL) METHANONE PHENYL AS INHIBITORS OF HIV VIRAL REPLICATION
JP5073480B2 (en) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド Antiviral resistance retroviral protease inhibitors
TW200613307A (en) 2004-05-17 2006-05-01 Tibotec Pharm Ltd 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
ATE481403T1 (en) 2004-05-17 2010-10-15 Tibotec Pharm Ltd SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDOÄ3,2- BÜINDOL-2-ONE DERIVATIVES USABLE AS PHARMACEUTICAL ANTIINFECTIVES
CN1953983B (en) 2004-05-17 2010-05-26 泰博特克药品有限公司 1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
MX2008012790A (en) 2006-04-03 2008-10-15 Tibotec Pharm Ltd Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones.
ZA200901162B (en) * 2006-09-04 2010-06-30 Panacea Biotec Ltd Programmable buoyant delivery technology
KR100809903B1 (en) * 2006-09-05 2008-03-06 주식회사유한양행 Stabilized clopidogrel-containing particles, processes for preparing the same, and pharmaceutical compositions comprising the same
CN101283984B (en) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 Core particle object coated by fungicide and polymer with high biological usage
JP2008280254A (en) * 2007-05-08 2008-11-20 Everest Pharm Industrial Co Ltd Core fine granule used in living body at high rate and prepared by being coated with disinfectant and polymer
US8313527B2 (en) 2007-11-05 2012-11-20 Allergan, Inc. Soft prosthesis shell texturing method
US8569364B2 (en) 2007-11-28 2013-10-29 Sequoia Pharmaceuticals, Inc. 5-substituted benzofurans as inhibitors of cytochrome P450 2D6
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US9050184B2 (en) 2008-08-13 2015-06-09 Allergan, Inc. Dual plane breast implant
US8877822B2 (en) 2010-09-28 2014-11-04 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
US11202853B2 (en) 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
AU2011252017B2 (en) * 2010-05-11 2015-07-16 Allergan, Inc. Porogen compositions, methods of making and uses
US8679279B2 (en) 2010-11-16 2014-03-25 Allergan, Inc. Methods for creating foam-like texture
CN102100678B (en) * 2011-02-18 2012-10-17 天津力生制药股份有限公司 Itraconazole sulfate capsules and method for preparing same
EP2931490A1 (en) 2012-12-13 2015-10-21 Allergan, Inc. Device and method for making a variable surface breast implant
US10092392B2 (en) 2014-05-16 2018-10-09 Allergan, Inc. Textured breast implant and methods of making same
MX2018008694A (en) 2016-01-20 2019-05-15 Theravida Inc Methods and compositions for treating hyperhidrosis.
BR112020020941A2 (en) * 2018-04-16 2021-03-02 Bristol-Myers Squibb Company apixaban formulations
CN114767636B (en) * 2022-04-11 2023-11-07 苏州中化药品工业有限公司 Itraconazole pellets, preparation method and itraconazole pellet capsule

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (en) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
AU731704B2 (en) * 1996-06-28 2001-04-05 Schering Corporation Oral composition comprising a triazole antifungal compound

Similar Documents

Publication Publication Date Title
RU99112123A (en) JEWELRY HAVING A NUCLEUS COATED WITH ANTI-FUN FUNCTION AND POLYMER
RU2218153C2 (en) Nucleus-bearing drops coated with antifungal agent and polymer
RU95108537A (en) GRANULA, METHOD FOR PRODUCING IT AND PHARMACEUTICAL COMPOSITION
SI9300461B (en) Beads having a core coated with an antifugal and a polymer
Khandbahale Microencapsulation-A novel approach in drug delivery: A review
RU2000120913A (en) GRANULES HAVING A NUCLEUS COATED WITH AN ANTI-FUNGAL DRUG AND POLYMER
KR950005864B1 (en) Sustained-release formulation
JP2558396B2 (en) Controlled release formulation
JPH06508779A (en) Method for manufacturing beadlet-shaped medicinal substances
JP2560019B2 (en) Novel formulations controlling the release of active compounds and methods for their production
EP1123700B1 (en) Timed pulsatile drug delivery systems
US5246714A (en) Drug preparation
US4975284A (en) Controlled release means
JPH08506802A (en) Corrugated drug delivery system
NZ237418A (en) Controlled release of drug from micropellets of 170-750 microns diameter
US7022342B2 (en) Controlled release oral dosage form of beta-adrenergic blocking agents
CA2581775A1 (en) Dihydropyrimidine microcapsule - formulations
WO1994028882A1 (en) Multiparticulate pulsatile drug delivery system
WO2001000182A1 (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
Garg et al. Microencapsulation techniques in pharmaceutical formulation
WO2004110410A1 (en) Extended release composition containing tramadol
Friend Polyacrylate resin microcapsules for taste masking of antibiotics
Sachan et al. Controlled drug delivery through microencapsulation
JP2005075826A5 (en)
CA1268710A (en) Drug in bead form and process for preparing same